Veracyte Stock

Veracyte Debt

The Debt of Veracyte (VCYT) as of Aug 13, 2026 is -725.16 M USD. In the previous year, Debt was -478.17 M USD — a change of 51.65% (lower).

Debt

-725.16 MUSD

YoY

51.65%

Last updated:

In 2026, Veracyte's total debt was -725.16 M USD, a 51.65% change from the -478.17 M USD total debt recorded in the previous year.

Access this data via the Eulerpool API

Veracyte Stock analysis

What does Veracyte do? Veracyte Inc is a company that specializes in the development and marketing of diagnostic tests for a wide range of diseases and disorders. The company was founded in 2008 and is headquartered in South San Francisco, California. The history of Veracyte Inc begins with the vision to help patients with better diagnostic options. The company has used its expertise in gene expression technology to develop tests that facilitate the diagnosis of diseases and disorders in various areas, such as cancer, thyroid diseases, and lung diseases. Veracyte Inc's business model is based on selling diagnostic tests to healthcare facilities, hospitals, doctors, and other medical institutions. The tests are performed by specially trained professionals and can provide a precise diagnosis that helps doctors plan individualized treatment. Veracyte Inc is divided into different divisions to offer the best and most precise test for each area. The divisions include cancer diagnosis, thyroid diagnostics, lung diagnostics, and other areas of gene expression technology. In cancer diagnosis, Veracyte Inc offers tests for various types of cancer, such as breast cancer, thyroid cancer, and lung cancer. The tests use RNA sequencing to analyze the patient's genetic information and provide a more precise diagnosis. In thyroid diagnostics, Veracyte Inc offers tests for various thyroid diseases that are often difficult to diagnose. The tests help avoid unnecessary surgeries or medical interventions and enable patients to receive a more accurate diagnosis and treatment. In lung diagnostics, Veracyte Inc offers tests for pneumonia, lung cancer, and other lung diseases. The tests use RNA sequencing and imaging to provide accurate diagnoses that help doctors recommend tailored treatment. In addition to these divisions, Veracyte Inc also offers other products and services, such as information campaigns and training for healthcare professionals, as well as support and counseling for patients and their families. Overall, Veracyte Inc aims to revolutionize the medical field and provide patients with better diagnosis and treatment options. The company's tests offer doctors and patients a more precise and personalized diagnosis, allowing for individualized treatment and achieving the best results. Veracyte is one of the most popular companies on Eulerpool.

Debt Details

Understanding Veracyte's Debt Structure

Veracyte's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Veracyte's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Veracyte’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Veracyte’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Veracyte stock

Debt of Veracyte is -725.16 M USD in 2026.

Debt of Veracyte changed from -478.17 M USD to -725.16 M USD, representing a 51.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Veracyte since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Veracyte historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Veracyte

All Key Metrics — Veracyte